Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 2/20 | 0.30 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17035806 | 0.93 | CYP11B1 (0.34) | CYP11B1CYP11B2PDE3BPDE3ACYP3A4 | |
| SCHEMBL20083383 | 0.88 | CYP11B1 (0.37) | CYP11B1CYP11B2KIF11ALOX5APFEN1 | |
| SCHEMBL20083435 | 0.88 | CYP11B1 (0.37) | CYP11B1CYP11B2KIF11ALOX5APFEN1 | |
| SCHEMBL2741550 | 0.87 | CYP11B1 (0.35) | CYP11B1CYP11B2CYP3A4CYP2C9APP | |
| SCHEMBL21919557 | 0.87 | CYP11B1 (0.35) | CYP11B1CYP11B2CYP3A4CYP2C9APP | |
| SCHEMBL13615257 | 0.86 | CYP11B1 (0.34) | CYP11B1CYP11B2PDE3BPDE3ACYP3A4 | |
| SCHEMBL19557547 | 0.85 | CYP11B1 (0.43) | CYP11B1CYP11B2PDE3BPDE3ACYP3A4 | |
| SCHEMBL2741551 | 0.84 | GRM2 (0.36) | CYP11B1CYP11B2ALOX5APFEN1 | |
| SCHEMBL16501319 | 0.84 | PDE3B (0.38) | CYP11B1CYP11B2PDE3BPDE3ACYP3A4 | |
| SCHEMBL19687728 | 0.84 | CYP11B1 (0.34) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10982149-B2 | Chiral compounds | MERCK PATENT GMBH (DE) | 2021-04-20 | — | — | US | disclosed |
| EP-3334801-B1 | MATERIAL COMBINATION | MERCK PATENT GMBH (DE) | 2020-05-27 | — | — | EP | disclosed |
| EP-2714843-B2 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY DEVICE | MERCK PATENT GMBH (DE) | 2019-10-30 | — | — | EP | disclosed |
| EP-3359625-B1 | CHIRAL COMPOUNDS | MERCK PATENT GMBH (DE) | 2019-10-23 | — | — | EP | disclosed |
| US-10450509-B2 | Liquid crystal medium and liquid display | MERCK PATENT GMBH (DE) | 2019-10-22 | — | — | US | disclosed |
| EP-3328963-B1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-20180223189-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2018-08-09 | — | — | US | disclosed |
| US-20180223189-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2018-08-09 | — | — | US | disclosed |
| EP-3090033-B1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2018-07-04 | — | — | EP | disclosed |
| EP-2925834-B1 | LENS ELEMENT | MERCK PATENT GMBH (DE) | 2018-07-04 | — | — | EP | disclosed |
| US-20140225035-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140158934-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| US-20140158934-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| US-20140077130-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2014-03-20 | — | — | US | disclosed |
| US-20140077130-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2014-03-20 | — | — | US | disclosed |
| EP-2708587-A1 | Liquid crystal medium and liquid crystal display | Merck Patent GmbH (DE) | 2014-03-19 | — | — | EP | disclosed |
| US-8659737-B2 | Liquid crystal medium and liquid crystal display | MERCK PATENT GMBH (DE) | 2014-02-25 | — | — | US | disclosed |
| US-8659737-B2 | Liquid crystal medium and liquid crystal display | MERCK PATENT GMBH (DE) | 2014-02-25 | — | — | US | disclosed |
| EP-2568032-A2 | Liquid crystal medium and liquid crystal display | Merck Patent GmbH (DE) | 2013-03-13 | — | — | EP | disclosed |
| US-20130057947-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10982149-B2 | Chiral compounds | FANCI, COL1A1, LCP1 | CYP11B1 2014/4885CYP11B2 2615/4885PDE3B 942/4885 |
| US-10450509-B2 | Liquid crystal medium and liquid display | NEFM, CRY1, BMP2 | CYP11B1 4063/4885CYP11B2 3871/4885PDE3B 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.